SEARCH

SEARCH BY CITATION

References

  • 1
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847. MEDLINE
  • 2
    Todo S, DeMetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13:619629. MEDLINE
  • 3
    Belle HS, Beringer KC, Detre KM. An update on liver transplantation in the US: Recipient characteristics and outcome. In: TerasakiPI, CeckaJM (eds). Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1995:115.
  • 4
    Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343:142146. MEDLINE
  • 5
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:16571661. MEDLINE
  • 6
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 384:12121215.
  • 7
    Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effects of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997; 63:393396. MEDLINE
  • 8
    Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:15811586. MEDLINE
  • 9
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713. MEDLINE
  • 10
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717. MEDLINE
  • 11
    Ben-Ari Z, Zemel R, Kazetsker A, Fraser G, Tur-Kaspa R. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after transplantation. Am J Gastroenterol 1999; 94:663667. MEDLINE
    Direct Link:
  • 12
    Tur-Kaspa R, Klein A, Aharonson SH. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992; 16:13381342. MEDLINE
  • 13
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implications. J Hepatol 1992; 14:104111. MEDLINE
  • 14
    Muller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, et al. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991; 13:9096. MEDLINE
  • 15
    Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26:13931395. MEDLINE
  • 16
    Dodson SF, Balan V, Shakil O, Bonham A, Rakela J, Fung JJ. Lack of efficacy of lamivudine for HBV infection after liver transplantation [abstract]. Hepatology 1998; 28:262A.
  • 17
    Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986; 83:16271633. MEDLINE
  • 18
    Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:43984402. MEDLINE
  • 19
    McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rate in treatment of recurrence but universal prevention if used as prophylaxis with very low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5:512519. MEDLINE
  • 20
    Ben-Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68:232236. MEDLINE
  • 21
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine-resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107113. MEDLINE
  • 22
    Fabia R, Levy MF, Crippin J, Tillery W, Netto GJ, Aguanno J, et al. De novo hepatitis B infection after liver transplantation: Source of disease, incidence, and impact. Liver Transpl Surg 1998; 4:119127. MEDLINE
  • 23
    Crespo J, Fabrega E, Casafont F, Rivero M, Heras G, de la Pena J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999; 5:175183. MEDLINE
  • 24
    Andreone P, Caraceni P, Grazi GL, Belli L, Milander GL, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after transplantation. J Hepatol 1998; 29:985989. MEDLINE